{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:33:29Z","timestamp":1760056409576,"version":"build-2065373602"},"reference-count":20,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T00:00:00Z","timestamp":1694649600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diagnostic Microbiology and Infectious Disease"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.diagmicrobio.2023.115969","type":"journal-article","created":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T02:21:14Z","timestamp":1682475674000},"page":"115969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Nirmatrelvir\/ritonavir use in patients with COVID-19 on hemodialysis: a case series"],"prefix":"10.1016","volume":"107","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6398-1318","authenticated-orcid":false,"given":"Ai-hua","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zong-li","family":"Diao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-ming","family":"Guan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying-jie","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dong-li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-chao","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong-dong","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wen-hu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.115969_bib0001","doi-asserted-by":"crossref","first-page":"175","DOI":"10.3390\/v15010175","article-title":"Risk factors of severe COVID-19: a review of host, viral and environmental factors","volume":"15","author":"Zsichla","year":"2023","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/j.diagmicrobio.2023.115969_bib0002","doi-asserted-by":"crossref","first-page":"107","DOI":"10.3390\/vaccines11010107","article-title":"Paxlovid (Nirmatrelvir and Ritonavir) use in pregnant and lactating woman: current evidence and practice guidelines-a scoping review","volume":"11","author":"Chourasia","year":"2023","journal-title":"Vaccines (Basel)"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115969_bib0003","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antibiotics11020220","article-title":"Oral nirmatrelvir\/ritonavir therapy for COVID-19: the dawn in the dark?","volume":"11","author":"Hung","year":"2022","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.diagmicrobio.2023.115969_bib0004","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.2402","article-title":"Efficacy and safety of nirmatrelvir\/ritonavir (Paxlovid) for COVID-19: a rapid review and meta-analysis","author":"Amani","year":"2022","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115969_bib0005","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.28471","article-title":"Nirmatrelvir-ritonavir for the treatment of COVID-19 patients: a systematic review and meta-analysis","volume":"95","author":"Cheema","year":"2023","journal-title":"J Med Virol"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115969_bib0006","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.3390\/ijms24021712","article-title":"Hemodialysis-associated immune dysregulation in SARS-CoV-2-infected end-stage renal disease patients","volume":"24","author":"Gonz\u00e1lez-Cuadrado","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.115969_bib0007","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.cmi.2023.01.016","article-title":"Immunologic characterization of a patient with clinical and virologic rebound upon nirmatrelvir\/ritonavir: the unfortunate epilogue of COVID-19","volume":"29","author":"Marchetti","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"5","key":"10.1016\/j.diagmicrobio.2023.115969_bib0008","doi-asserted-by":"crossref","first-page":"352","DOI":"10.5501\/wjv.v11.i5.352","article-title":"Mortality rate of COVID-19 infection in end stage kidney disease patients on maintenance hemodialysis: A systematic review and meta-analysis","volume":"11","author":"Cancarevic","year":"2022","journal-title":"World J Virol"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2023.115969_bib0009","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01229-22","article-title":"Pharmacokinetics of nirmatrelvir and ritonavir in COVID-19 patients with end-stage renal disease on intermittent hemodialysis","volume":"66","author":"Lingscheid","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"issue":"8","key":"10.1016\/j.diagmicrobio.2023.115969_bib0010","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.2215\/CJN.05270522","article-title":"Prescribing nirmatrelvir\/ritonavir for COVID-19 in advanced CKD","volume":"17","author":"Hiremath","year":"2022","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.115969_bib0011","doi-asserted-by":"crossref","first-page":"485","DOI":"10.2215\/CJN.0000000000000107","article-title":"Early experience with modified dose nirmatrelvir\/ritonavir in dialysis patients with coronavirus disease 2019","volume":"18","author":"Hiremath","year":"2023","journal-title":"Clin J Am Soc Nephrol"},{"issue":"13","key":"10.1016\/j.diagmicrobio.2023.115969_bib0012","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.3390\/jcm11133759","article-title":"Immune system dysfunction and inflammation in hemodialysis patients: two sides of the same coin","volume":"11","author":"Campo","year":"2022","journal-title":"J Clin Med"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2023.115969_bib0013","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3390\/v14112540","article-title":"Oral antiviral treatment for COVID-19: a comprehensive review on nirmatrelvir\/ritonavir","volume":"14","author":"Akinosoglou","year":"2022","journal-title":"Viruses"},{"issue":"4","key":"10.1016\/j.diagmicrobio.2023.115969_bib0014","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cpt.2688","article-title":"Pharmacokinetics of oral nirmatrelvir\/ritonavir, a protease inhibitor for treatment of COVID-19, in subjects with renal impairment","volume":"112","author":"Toussi","year":"2022","journal-title":"Clin Pharmacol Ther"},{"issue":"15","key":"10.1016\/j.diagmicrobio.2023.115969_bib0015","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1056\/NEJMoa2118542","article-title":"Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19","volume":"386","author":"Hammond","year":"2022","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115969_bib0016","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s40267-022-00971-1","article-title":"Nirmatrelvir plus ritonavir in COVID-19: a profile of its use","volume":"39","author":"Blair","year":"2023","journal-title":"Drugs Ther Perspect"},{"issue":"2","key":"10.1016\/j.diagmicrobio.2023.115969_bib0017","doi-asserted-by":"crossref","first-page":"106708","DOI":"10.1016\/j.ijantimicag.2022.106708","article-title":"Nirmatrelvir and COVID-19: development, pharmacokinetics, clinical efficacy, resistance, relapse, and pharmacoeconomics","volume":"61","author":"Focosi","year":"2023","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"10.1016\/j.diagmicrobio.2023.115969_bib0018","doi-asserted-by":"crossref","first-page":"2356","DOI":"10.1016\/j.ekir.2022.08.026","article-title":"Safety, efficacy, and relapse of nirmatrelvir-ritonavir in kidney transplant recipients infected with SARS-CoV-2","volume":"7","author":"Devresse","year":"2022","journal-title":"Kidney Int Rep"},{"issue":"12","key":"10.1016\/j.diagmicrobio.2023.115969_bib0019","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0167854","article-title":"Apparent hypothalamic-pituitary-adrenal axis suppression via reduction of interleukin-6 by glucocorticoid therapy in systemic autoimmune diseases","volume":"11","author":"Fujio","year":"2016","journal-title":"PLoS One"},{"issue":"22","key":"10.1016\/j.diagmicrobio.2023.115969_bib0020","first-page":"22413","article-title":"Estimating the release of inflammatory factors and use of glucocorticoid therapy for COVID-19 patients with comorbidities","volume":"12","author":"Han","year":"2020","journal-title":"Aging (Albany NY)"}],"container-title":["Diagnostic Microbiology and Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323000792?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0732889323000792?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T10:00:20Z","timestamp":1760004020000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0732889323000792"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":20,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,11]]}},"alternative-id":["S0732889323000792"],"URL":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115969","relation":{},"ISSN":["0732-8893"],"issn-type":[{"type":"print","value":"0732-8893"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nirmatrelvir\/ritonavir use in patients with COVID-19 on hemodialysis: a case series","name":"articletitle","label":"Article Title"},{"value":"Diagnostic Microbiology and Infectious Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diagmicrobio.2023.115969","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"115969"}}